• Mob: +994777276006  Mob: +994777276006
  • office@makromed.az [email protected]
Makromed Logo
  • Home
  • About
    • About
    • Company Legal Structure
    • Gallery
    • Contact
  • Services
    • Pharmacovigilance
    • Registration of the medicine
    • Registration of Food supplements (FS)
    • Other services
    • Projection and design
  • Products
    • Medicine
    • Food supplements
    • Hygiene product
    • Medical device
    • Cosmetic product
  • Pharmacovigilance
    • Online notifications
  • Training
  • Information
    • Blog
    • News
    • Legislation

Clinical studies of Lynparza were stopped in phase 3 due to futility

  1. Home
  2. News
  3. Clinical studies of Lynparza were stopped in phase 3 due to futility

Categories

  • Medicine
  • Drug
  • Interesting
  • World
  • Azerbaijan
Makromed

If you haven't found the answers to your questions in our Frequently Asked Questions section, don't worry - we're here to help!

Contact Us
Clinical studies of Lynparza were stopped in phase 3 due to futility

Clinical studies of Lynparza were stopped in phase 3 due to futility

Merck (NYSE:MRK) has announced that it will stop the Phase 3 LYNK-003 trial focused on Lynparza (olaparib) with or without bevacizumab for patients with unresectable or metastatic colorectal cancer. Two experimental arms in the trial, one focused on Lynparza as monotherapy or in combination with the immunotherapy drug bevacizumab, will be suspended. The primary endpoint of the trial was progression-free survival. The study focused on patients without progression after first-line therapy.

Merck made the decision after receiving feedback from an independent Data Monitoring Committee (DMC) following review from an interim analysis. The PARP inhibitor Lynparza was first developed by KuDOS Pharmaceuticals and the University of Pennsylvania. AstraZeneca acquired KuDOS Pharmaceuticals in 2005.

In 2021, the drug jointly earned AstraZeneca and Merck $3.7 billion. The two companies continue to develop Lynparza for a variety of oncology indications, including metastatic breast, prostate, ovarian and pancreatic cancer. The drug first won FDA approval for maintenance treatment of ovarian cancer in 2017. MRK shares dipped 2.76% to $92.34 while AZN shares were up 0.63% to £11,200.00.

 

Source: https://www.drugdiscoverytrends.com/

Makromed Logo White

MAKROMED LLC is one of the best and leading qualified consulting companies in Azerbaijan established in 2013. Now it’s a part ...

Usefull links

  • Blog
  • News
  • Legislation
  • Gallery

Training

  • Active trainings
  • Deaktive trainings
  • Structure
  • Pharmacovigilance

Services

  • Pharmacovigilance
  • Registration of the medicine
  • Registration of Food supplements (FS)
  • Other services
  • Projection and design

Contact

Mob: +994777276006

Mob: +994777276006 Tel/Fax: +994124098090

office@makromed.az

[email protected]

Binagadi  district ,Svetlana Mammadova 203C Baku , Azerbaijan AZ1114

Binagadi district ,Svetlana Mammadova 203C Baku , Azerbaijan AZ1114

©2025 Makromed.az All rights reserved

  • About
  • Pharmacovigilance
  • Products
  • Contact